IL3RA and CD4+/CD56+ hematodermic neoplasm: Furthermore, antigen loss has been observed following CAR T‐cell therapy targeting CD123 in BPDCN, in which CD123‐negative populations were identified either lacking CD123 DNA or expressing isoforms without the required epitope, and may be an alternative mechanism which can lead to PVEK resistance.32